RTK logo

RTK and Partner
News and Events



June 14, 2022

An early-stage advisory and investment fund supporting emerging technologies in the biotech and pharmaceutical sector, today announced its participation in seed-round capital funding of Unravel Biosciences, Inc. ("Unravel"). The financial terms of the transaction were not disclosed.

Click to read the full article

Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.

June 14, 2022

Scilex Holding Company has entered into a license and commercialization agreement with ROMEG Therapeutics for the exclusive right to market and distribute Gloperba, an oral solution for adults suffering from gout, in the US

Click to read the full article

Unravel Biosciences Partners with TMA Precision Health to Advance Drug Treatment for Rett Syndrome into the Clinic

July 5, 2022

Unravel Biosciences today announced a partnership with TMA Precision Health aimed at identifying rare Rett Syndrome patients for inclusion in Unravel's first-in-human reformulated drug trial.

Click to read the full article

Revolutionizing the Future of Healthcare

RTK is a biopharmaceutical advisory and investment fund that supports companies
by enabling them to develop promising technologies and reach their potential to benefit patients.

We have one goal: to enable better patient lives and a better world through better healthcare. We take great satisfaction in partnering with companies having high potential to disrupt the healthcare ecosystem and helping support high‐performing management teams to realize their goals.

Contact Us